Additionally, the “gamechanger” jab may be able to prevent kidney, lung, and bladder cancer.
Each person has a unique one that instructs the body to recognize cancer cells and prevent the illness from recurring.
A third trial has been started after a stage-two trial revealed that it greatly decreased the chance of cancer returning in melanoma patients.
The phase is being led by University College London Hospitals NHS Foundation Trust (UCLH).
The trial’s co-ordinating investigator, Dr. Heather Shaw, described it as “one of the most exciting things we’ve seen in a really long time”.
She added, “This is a really well-honed tool.”
